These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 17360488)

  • 1. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1.
    Schröfelbauer B; Hakata Y; Landau NR
    Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4130-5. PubMed ID: 17360488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction.
    Wu Y; Zhou X; Barnes CO; DeLucia M; Cohen AE; Gronenborn AM; Ahn J; Calero G
    Nat Struct Mol Biol; 2016 Oct; 23(10):933-940. PubMed ID: 27571178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.
    Belzile JP; Duisit G; Rougeau N; Mercier J; Finzi A; Cohen EA
    PLoS Pathog; 2007 Jul; 3(7):e85. PubMed ID: 17630831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation.
    Ahn J; Vu T; Novince Z; Guerrero-Santoro J; Rapic-Otrin V; Gronenborn AM
    J Biol Chem; 2010 Nov; 285(48):37333-41. PubMed ID: 20870715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest.
    Hakata Y; Miyazawa M; Landau NR
    Virol J; 2014 Jun; 11():108. PubMed ID: 24912982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle.
    Hrecka K; Gierszewska M; Srivastava S; Kozaczkiewicz L; Swanson SK; Florens L; Washburn MP; Skowronski J
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11778-83. PubMed ID: 17609381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest.
    Tan L; Ehrlich E; Yu XF
    J Virol; 2007 Oct; 81(19):10822-30. PubMed ID: 17626091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover.
    Wen X; Casey Klockow L; Nekorchuk M; Sharifi HJ; de Noronha CM
    PLoS One; 2012; 7(1):e30939. PubMed ID: 22292079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins.
    Hrecka K; Hao C; Shun MC; Kaur S; Swanson SK; Florens L; Washburn MP; Skowronski J
    Proc Natl Acad Sci U S A; 2016 Jul; 113(27):E3921-30. PubMed ID: 27335459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.
    Schröfelbauer B; Yu Q; Zeitlin SG; Landau NR
    J Virol; 2005 Sep; 79(17):10978-87. PubMed ID: 16103149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Vpr Protein Enhances Proteasomal Degradation of MCM10 DNA Replication Factor through the Cul4-DDB1[VprBP] E3 Ubiquitin Ligase to Induce G2/M Cell Cycle Arrest.
    Romani B; Shaykh Baygloo N; Aghasadeghi MR; Allahbakhshi E
    J Biol Chem; 2015 Jul; 290(28):17380-9. PubMed ID: 26032416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development.
    McCall CM; Miliani de Marval PL; Chastain PD; Jackson SC; He YJ; Kotake Y; Cook JG; Xiong Y
    Mol Cell Biol; 2008 Sep; 28(18):5621-33. PubMed ID: 18606781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vpr expression abolishes the capacity of HIV-1 infected cells to repair uracilated DNA.
    Eldin P; Chazal N; Fenard D; Bernard E; Guichou JF; Briant L
    Nucleic Acids Res; 2014 Feb; 42(3):1698-710. PubMed ID: 24178031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system.
    DeHart JL; Zimmerman ES; Ardon O; Monteiro-Filho CM; Argañaraz ER; Planelles V
    Virol J; 2007 Jun; 4():57. PubMed ID: 17559673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages.
    Lahouassa H; Blondot ML; Chauveau L; Chougui G; Morel M; Leduc M; Guillonneau F; Ramirez BC; Schwartz O; Margottin-Goguet F
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5311-6. PubMed ID: 27114546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase.
    Le Rouzic E; Belaïdouni N; Estrabaud E; Morel M; Rain JC; Transy C; Margottin-Goguet F
    Cell Cycle; 2007 Jan; 6(2):182-8. PubMed ID: 17314515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the interactions and role of DCAF1/VPRBP in the DDB1-cullin4A E3 ubiquitin ligase complex engaged by HIV-1 Vpr to induce a G2 cell cycle arrest.
    Gérard FC; Yang R; Romani B; Poisson A; Belzile JP; Rougeau N; Cohen ÉA
    PLoS One; 2014; 9(2):e89195. PubMed ID: 24558487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest.
    Belzile JP; Richard J; Rougeau N; Xiao Y; Cohen EA
    J Virol; 2010 Apr; 84(7):3320-30. PubMed ID: 20089662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Vpr hijacks EDD-DYRK2-DDB1
    Hossain D; Ferreira Barbosa JA; Cohen ÉA; Tsang WY
    J Biol Chem; 2018 Jun; 293(24):9448-9460. PubMed ID: 29724823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Mass Spectrometry-Based Profiling of Interactomes of Viral DDB1- and Cullin Ubiquitin Ligase-Binding Proteins Reveals NF-κB Inhibitory Activity of the HIV-2-Encoded Vpx.
    Landsberg CD; Megger DA; Hotter D; Rückborn MU; Eilbrecht M; Rashidi-Alavijeh J; Howe S; Heinrichs S; Sauter D; Sitek B; Le-Trilling VTK; Trilling M
    Front Immunol; 2018; 9():2978. PubMed ID: 30619335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.